Discussion topic and resource: This study focused on the benefits of triple therapy for chronic obstruction pulmonary disease (COPD) with an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long acting B2 agonist (LABA), as compared with dual therapy (either inhaled glucocorticoid-LABA or LAMA-LABA).
Reference: Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. The New England journal of medicine; Published on April 18, 2018 at NEJM.org
Lead by: Dr. Tourin,
Hosted by Paula Matt and Lisa Fasciani – GSK
Duration: 45 minutes
Discussion: The evaluation of the effects of 52 weeks of a once daily combination of fluticasone furoate (an inhaled glucocorticoid), umeclidinium ( a LAMA) and vilanterol (a LABA), as compared with fluticasone furoate-vilanterol or the dual bronchodilator umeclidinium-vilanterol on the rate of moderate or severe COPD exacerbations. Each regimen was administered in a single dry-powered inhaler (Ellipta, Glaxosmothkline).
Patients enrolled were 40 years of age or older and had symptomatic COPD (COPD Assessment Test [CAT] score, > 10; range 0-40 with higher score indicating more symptoms; minimal clinically important difference 2 units).
Conclusion: Triple therapy with fluticasone furoate, umeclidinium, and vilantertol resulted in a lower rate of moderate or severe COPD exacerbations than fluticasone furoate-vilanterol or umeclidinium-vilanterol in this population. Triple therapy also resulted in lower rate of hospitalization due to COPD than umeclidinium-vilanterol.
-Paula Matte, Rep (GSK); Lisa, Rep (GSK); Olga Tourin, MD; Tammy Glas, RRT; Andrew Li, RRT; Pavel Tourin,; Stephanie Dick LPN